ArticleClinical infectious diseases : an official publication of the Infectious Diseases Society of America2022
Vaccine Impact and Effectiveness of Meningococcal Serogroup ACWY Conjugate Vaccine Implementation in the Netherlands: A Nationwide Surveillance Study.
Article in Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Genomic and evolutionary insights into a novelMicrobial genomics · 2026Article
- Evaluation of the MenACWY Vaccination Catch-Up Campaign Among Adolescents in Madrid: Coverage, Trends, and Determinants.Vaccines · 2026Article
- Genomic characterization of invasiveEmerging microbes & infections · 2025Article
- Parents' preference for the inclusion of pediatric vaccines in the Chinese National Immunization Program: A discrete choice experiment.Human vaccines & immunotherapeutics · 2025Article
- Article
- Modeling antibody persistence after MenACYW-TT vaccination and comparative analysis with other quadrivalent meningococcal vaccines.Scientific reports · 2025Article
- Challenges and Prospects for Eradication ofPathogens (Basel, Switzerland) · 2025Review
- Article
- Public health impact and cost-effectiveness of introducing MenACWY vaccination strategies in Germany.BMC public health · 2025Article
- Economic Evaluation of Adolescent Vaccination with Serogroup ACWY and C Meningococcal Vaccines in Germany.Infectious diseases and therapy · 2025Article
- A Phase 3B, Open-Label Study to Evaluate the Immunogenicity and Safety of the Quadrivalent Meningococcal NimenrixInfectious diseases and therapy · 2025Article
- Quadrivalent Conjugate Vaccine and Invasive Meningococcal Disease in US Adolescents and Young Adults.JAMA network open · 2024Article
- A literature review and evidence-based evaluation of the Dutch national immunisation schedule yield possibilities for improvements.Vaccine: X · 2024Review
- Modelling the Public Health Impact of MenACWY and MenC Adolescent Vaccination Strategies in Germany.Infectious diseases and therapy · 2024Article
- Changing patterns of invasive meningococcal disease and future immunization strategies.Human vaccines & immunotherapeutics · 2023Article
- Article
- Meningococcal Disease in the Post-COVID-19 Era: A Time to Prepare.Infectious diseases and therapy · 2023Article
- Real-world impact and effectiveness of MenACWY-TT.Human vaccines & immunotherapeutics · 2023Review
- Article
- Epidemiology of invasive meningococcal disease worldwide from 2010-2019: a literature review.Epidemiology and infection · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIn response to the recent serogroup W invasive meningococcal disease (IMD-W) epidemic in the Netherlands, meningococcal serogroup C (MenC) conjugate vaccination for children aged 14 months was replaced with a MenACWY conjugate vaccination, and a mass campaign targeting individuals aged 14-18 years was executed. We investigated the impact of MenACWY vaccination implementation in 2018-2020 on incidence rates and estimated vaccine effectiveness (VE).
methodsWe extracted IMD cases diagnosed between July 2014 and December 2020 from the national surveillance system. We calculated age group-specific incidence rate ratios by comparing incidence rates before (July 2017-March 2018) and after (July 2019-March 2020) MenACWY vaccination implementation. We estimated VE in vaccine-eligible cases using the screening method.
resultsOverall, the IMD-W incidence rate declined by 61% (95% confidence interval [CI], 40 to 74). It declined by 82% (95% CI, 18 to 96) in the vaccine-eligible age group (individuals aged 15-36 months and 14-18 years) and by 57% (95% CI, 34 to 72) in vaccine-noneligible age groups. VE was 92% (95% CI, -20 to 99.5) in vaccine-eligible toddlers (aged 15-36 months). No IMD-W cases were reported in vaccine-eligible teenagers after the campaign.
conclusionsThe MenACWY vaccination program was effective in preventing IMD-W in the target population. The IMD-W incidence reduction in vaccine-noneligible age groups may be caused by indirect effects of the vaccination program. However, disentangling natural fluctuation from vaccine effect was not possible. Our findings encourage the use of toddler and teenager MenACWY vaccination in national immunization programs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.